Navigation Links
Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
Date:6/22/2013

ional diabetes fact sheet: national estimates and general information on diabetes and pre-diabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Center for Disease Control and Prevention, 2011.
  • International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact Sheet. 2012.
  • International Diabetes Federation. Diabetes Atlas, 5th Edition: What is Diabetes? http://www.idf.org/diabetesatlas/5e/what-is-diabetes. Accessed on: June 18, 2013.
  • American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033-1046.
  • * Empagliflozin is an investigational compound. Its safety and efficacy have not been established.

    (Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

    (Logo: http://photos.prnewswire.com/prnh/20110825/DE57898LOGO )

     


    '/>"/>
    SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
    2. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
    3. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
    4. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
    5. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
    6. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
    7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
    8. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
    9. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
    10. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
    11. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical ... Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it ... to address a potential issue with a clip ... the Axilla application of the SAM Junctional Tourniquet ...
    (Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PRNewswire/ ... Medina Medical as CEO and member of the Board ... three decades of medical device development and commercialization experience, ... Medical,s field. Mr. Engelson previously served as a Partner ... served as President and CEO of two Foundry start-ups. ...
    (Date:8/29/2014)... -- Research and Markets has announced the ... & Pipeline Insight 2014" report to their offering. ... and eradicate the prevalence of cancer have achieved limited ... low specificity, safety and large number of side effects, ... solution. It has been discovered that peptides can be ...
    Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
    ... Aug. 5, 2011 Varian Medical Systems, Inc. (NYSE: ... former CEO and member of the Board of Directors for ... of management in global medical device businesses, has been appointed ... Varian,s Board of Directors also increased its size from nine ...
    ... FOREST, Ill., Aug. 5, 2011 Hospira, Inc. (NYSE: ... today announced U.S. Food and Drug Administration (FDA) approval of ... presentations include 200 mg, 1 gm and 2 gm with ... sales of more than $750 million in 2010, led by ...
    Cached Medicine Technology:Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 2Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 3
    (Date:8/30/2014)... 30, 2014 Hundreds of Byetta lawsuits ... to move forward in U.S. courts, Bernstein Liebhard LLP ... on July 31, 2014, Byetta and Bydureon (an extended-release ... liability claims that allege the drugs caused pancreatitis, pancreatic ... of these claims are pending in a multidistrict litigation ...
    (Date:8/30/2014)... Springs, CO (PRWEB) August 30, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) rob people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
    (Date:8/30/2014)... 2014 Market Research Report on ... a professional and in-depth market survey on Global ... reviews the basic information of Lab Oven including ... then explores global and China’s top manufacturers of ... value, and market share etc. , The report ...
    (Date:8/30/2014)... 30, 2014 The federal judge ... ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. ... cases selected for one of the proceeding’s bellwether ... 18, 2014, U.S. District Judge Joseph R. Goodwin ... with Boston Scientific’s contention that a consolidated trial ...
    (Date:8/30/2014)... 30, 2014 In today’s world, a ... difficult to get. Snoring and sleep apnea (a medical ... stops) robs people and their bed partners of the ... to 45% of the population snores and 20 million ... Of these, only 10% have been diagnosed and treated; ...
    Breaking Medicine News(10 mins):Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
    ... Spanish . , The " La Mente Bilinge " ... Arts at the University of the Basque Country analyses bilingual processing ... acquires and manages languages and to discover in what way languages ... In order to understand how we become fluent in a language ...
    ... make healthy choices, study shows , , MONDAY, June 30 (HealthDay News) ... serving of baked or fried food bad for you, or can ... no amount of the artery-clogging artificial fat is good for ... panel found on the side of grocery store products does a ...
    ... on Outstanding Quality and Compliance -, LEXINGTON, ... that it has received the prestigious Supplier,Performance Award ... The,award recognizes outstanding performance in quality and compliance ... as award winners. IL,was presented with the honor ...
    ... WEST CONSHOHOCKEN, Pa., June 30 Cadient Group, ... today announced that Stephen Wray, President and CEO ... Young Entrepreneur Of The Year(R) in the,Greater Philadelphia ... program,was designed to recognize outstanding entrepreneurs on a ...
    ... MUMBAI, India, June 30 Sun Pharmaceutical,Industries Ltd. ... today announced that Alkaloida Chemical Company Exclusive Group,Ltd. ... a tender offer,for all outstanding Ordinary Shares of ... share in cash., On May 18, 2007, ...
    ... Health Solutions Corp.,("SXC" or the "Company") (NASDAQ: ... and pharmacy benefits management services, announces a five ... benefit management,("PBM") services with The University of Toledo ... for more than 6,000 members of,UT,s employee prescription ...
    Cached Medicine News:Health News:Laka: 'Language exists in the brain' 2Health News:Laka: 'Language exists in the brain' 3Health News:Laka: 'Language exists in the brain' 4Health News:Trans Fat Labeling Gets Tricky 2Health News:Trans Fat Labeling Gets Tricky 3Health News:Trans Fat Labeling Gets Tricky 4Health News:Trans Fat Labeling Gets Tricky 5Health News:Instrumentation Laboratory Receives Performance Award from Premier for Second Consecutive Year 2Health News:Cadient Group President and CEO, Stephen Wray, Named 2008 Ernst & Young Entrepreneur Of The Year(R) in Greater Philadelphia Region 2Health News:Cadient Group President and CEO, Stephen Wray, Named 2008 Ernst & Young Entrepreneur Of The Year(R) in Greater Philadelphia Region 3Health News:Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share 2Health News:Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share 3Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 2Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 3
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... System is a panel mounted system that offers ... needs of the heath care professional using the ... available with a dual action lever that allows ... to an IV pole. Similarly, it features ...
    Medicine Products: